Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery. The main questions it aims to answer are: * 7-year ipsilateral breast tumor recurrence * 7-year disease-free survival * 7-year locoregional recurrence * 7-year overall survival * Adverse events of radiation therapy Participants will be assessed by multi-dimensional methods after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki kobiety w wieku co najmniej 19 lat
- •Potwierdzony nowotwór piersi HER2+ (rodzaj raka piersi)
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Świadoma zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Rak przewodowy piersi na wczesnym etapie (nie rozprzestrzeniający się)
- •Poprzednia radioterapia piersi po stronie choroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- June 29, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Samsung Medical Center
Seoul, South Korea
Trial contact
Haeyoung Kim, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.